Key Highlights
- First-quarter revenue reached $15.29B, surpassing the $14.94B consensus forecast
- Core earnings per share of $2.58 exceeded the $2.54 analyst projection
- Oncology division grew 16% compared to last year; rare disease segment climbed 15%
- Company reaffirms full-year outlook: mid-to-high single-digit revenue expansion, low double-digit core EPS increase
- Shares declined approximately 1% following the report, with market observers noting momentum already reflected in valuation
AstraZeneca opened Wednesday’s session with impressive quarterly figures, yet investor response was tepid. The British pharmaceutical giant reported first-quarter revenue of $15.29 billion, climbing from $13.59 billion in the same period last year and surpassing the $14.94 billion Wall Street consensus.
AstraZeneca $AZN Q1 revenue rose to $15.29B, above the $14.94B estimate, as strong cancer and rare-disease drug sales lifted results. Oncology now makes up about 44% of revenue. Core EPS was $2.58 vs. $2.54 est., and the company kept full-year guidance.
— Wall St Engine (@wallstengine) April 29, 2026
Core earnings per share registered at $2.58, exceeding analyst expectations of $2.54. Core operating profit expanded 12% to reach $4.25 billion.
Even with the positive results, AZN shares dropped roughly 1% during early London trading hours. Adam Vettese, an analyst with eToro, characterized the market’s response as “muted,” noting that traders had already factored in the company’s strong performance trajectory.
The oncology division continues to serve as the primary growth driver, representing 44% of total group revenue. Division sales expanded 16% year-over-year at constant exchange rates to $6.8 billion.
Imfinzi, utilized for bladder and lung cancer treatment, soared 30% to $1.7 billion. Tagrisso, targeting lung cancer patients, increased 5% to $1.8 billion. Enhertu, focused on breast and gastric cancer cases, surged 34% to $831 million.
The rare disease business unit also performed strongly, with revenues climbing 15% annually.
Oncology and Rare Disease Segments Power Growth
Revenue from the United States expanded 10% during the quarter, while Chinese market sales increased 2%. AstraZeneca has executed significant strategic initiatives in both territories over the past twelve months, including a $50 billion U.S. manufacturing agreement and a $15 billion investment pledge in China.
The pharmaceutical company also achieved an NYSE listing and obtained U.S. tariff exemptions via a drug pricing arrangement.
Net income for the first quarter climbed to $3.08 billion from $2.92 billion in the prior-year period.
Development Pipeline and 2030 Objectives Remain Intact
Chief Executive Pascal Soriot reinforced the firm’s ambitious $80 billion annual revenue objective for 2030. He indicated AstraZeneca is positioning itself for numerous product introductions and continues progressing toward more than 20 new launches by that milestone.
Three novel therapies could debut in the U.S. market this year subject to regulatory clearance: baxdrostat for hypertension management, camizestrant for specific breast cancer forms, and gefurulimab for chronic autoimmune conditions.
The full-year 2026 forecast remained unaltered. AstraZeneca anticipates mid-to-high single-digit revenue expansion and low double-digit core earnings per share growth measured in constant currencies.
Soriot cautioned last week that Europe faces the prospect of becoming merely a “sales office” for the pharmaceutical sector as it lags behind the U.S. and China. This backdrop underscores AstraZeneca’s ongoing efforts to strengthen its presence in both regions.
LSEG analysts project full-year 2026 sales expansion of 7.2% and profit growth of 11.2%, closely aligned with 2025 performance levels.
AstraZeneca’s stock price remained essentially flat year-to-date before today’s earnings release. The better-than-expected results did little to alter that trajectory.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
